Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.51 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486164 | 0.89 | KIT (0.52) | KITSRCABL1RETKDR | |
| SCHEMBL3182950 | 0.87 | RET (0.63) | KITSRCABL1RETKDR | |
| SCHEMBL4933270 | 0.87 | KIT (0.65) | KITSRCABL1RETBRAF | |
| SCHEMBL4929396 | 0.86 | KIT (0.52) | KITSRCABL1RETKDR | |
| SCHEMBL4929391 | 0.85 | KIT (0.53) | KITSRCABL1RETKDR | |
| SCHEMBL4939914 | 0.85 | KIT (0.52) | KITSRCABL1RETKDR | |
| SCHEMBL3166509 | 0.85 | KIT (0.51) | KITSRCABL1RETKDR | |
| SCHEMBL17182149 | 0.80 | MKNK2 (0.53) | KITSRCABL1RETKDR | |
| SCHEMBL12516824 | 0.80 | RET (0.62) | KITSRCABL1RETKDR | |
| SCHEMBL22477848 | 0.80 | KIT (0.64) | KITSRCABL1RETBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | KIT 1043/4885SRC 203/4885ABL1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.